Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ARIA (Aria.AI) fluctuates 46.1% in 24 hours: Whale Sell-offs and Net Capital Outflows Dominate

ARIA (Aria.AI) fluctuates 46.1% in 24 hours: Whale Sell-offs and Net Capital Outflows Dominate

Bitget PulseBitget Pulse2026/04/16 17:35
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, ARIA price rebounded sharply from a low of $0.08692 to a high of $0.12697, currently quoted at $0.12493, with a price swing of 46.1%. Trading volume increased significantly, with some platforms reporting 24-hour trading volume between $29.2 million and $202 million. There was a net outflow of funds, with major net capital outflow amounting to $6.1357 million.

Analysis of Abnormal Fluctuations

- Dominated by whale sell-offs: Strong selling pressure appeared within 24 hours, with prices briefly rallying from the low of $0.08854 before pulling back. Whale activities led to a net outflow exceeding $6 million.

- Trading volume surge amplified volatility: 24-hour trading volume soared to 2-3 times the market cap, accompanied by liquidation events, with total liquidations amounting to $406,700.

Market Views and Outlook

Market sentiment remains cautious. The mainstream view considers this volatility as a continuation of a flash crash, with concerns over further manipulation risks. Some analysts pointed to signs of a rebound (such as a rally of over 30% from the low), but emphasized high volatility and suggested caution regarding short-term correction pressure on AI meme coins, expecting consolidation in the near term.

Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23